Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etodolac + Cyclobenzaprine in Postoperative Pain Control After Impacted Third Molar Extraction
NCT03127592Phase 3Terminated
- Sponsor
- Apsen Farmacêutica
- Start
- Oct 2020
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of etodolac and cyclobenzaprine in acute pain (3 arms), sponsored by Apsen Farmacêutica. Primary endpoint: Superiority of the Fixed Dose Combination versus Isolated active substances at 4 hours. Started Oct 2020; status: terminated.
02
Drugs
etodolaccyclobenzaprine
03
Conditions
acute pain
Beyond the preview
Go deeper on NCT03127592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03127592.